JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey
Yildirim, Fatma; Baha, Ayse; Yurdakul, Ahmet Selim; Ozturk, Can;
  PDF(new window)
 Abstract
Purpose: To compare the efficacy and toxicity of gemcitabine versus docetaxel in a second-line setting of nonsmall cell lung cancer (NSCLC) patients previously treated with platin-based combination chemotherapy. Materials and Methods: We retrospectively evaluated the medical records of 57 patients treated with single agent gemcitabine or docetaxel in second-line setting of advanced NSCLC who received one prior platinum-based therapy. Results: The mean age was years with 55 (96.5%) males and two (3.5%) females. Forty of them received docetaxel and 17 gemcitabine. The mean number of chemotherapy cycles was in the gemcitabine group, while it was in the docetaxel group. Overall response rates were 8% and 12% (P
 Keywords
Gemcitabine and docetaxel;second-line therapy;advanced stage non-small cell lung cancer;
 Language
English
 Cited by
1.
Cationic Supramolecular Vesicular Aggregates for Pulmonary Tissue Selective Delivery in Anticancer Therapy, ChemMedChem, 2016, 11, 16, 1734  crossref(new windwow)
 References
1.
Burris H, Eckhardt J, Fields S, et al (1993). Phase II trial of Taxotere with non-small cell lung cancer. Proc Am Soc Clin Oncol, 12, 335.

2.
Cho KH Song YB, Choi IS, et al (2006). A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer. Jpn J Clin Oncol, 36, 50-4. crossref(new window)

3.
Cobo M, Gutierrez V, Alcaide J, et al (2007). A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced nonsmall- cell lung cancer and good performance status. Lung Cancer, 56, 255-62. crossref(new window)

4.
Coskun U, Kaya AO, Buyukberber S, et al (2008). Single agent gemcitabine in the second-line treatment of advanced nonsmall cell lung cancer after treatment with taxane + platinum regimens. Med Oncol, 25, 133-6. crossref(new window)

5.
Crino L, Mosconi AM, Scagliotti GV, et al (1999). Gemcitabine as second-line treatment for advanced non-small-cell lung cancer, A phase II trial. J Clin Oncol, 17, 2081-5.

6.
Fossella FV, De Vore R, Kerr RN, et al (2000). Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol, 18, 2354-62.

7.
Fossella FV, Lee JS, Shin DM, et al (1995). Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol, 13, 645-51.

8.
Gandara DR, Vokes E, Green M, et al (1997). Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer, a confirmation of prolonged survival in a multicenter trial. Proc Am Soc Clin Oncol, 16, 454a.

9.
Gillenwater HH, Tynan M, Natoli S, et al (2000). Second-line gemcitabine in refractory stage IV non-small-cell lung cancer, A phase II trial. Clin Lung Cancer, 2, 133-8. crossref(new window)

10.
Gridelli C, Perrone F, Gallo C, et al (1999). Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC), A phase II trial. Anticancer Res, 19, 4535-8.

11.
Hertel LW, Boder GB, Kroin JS, et al (1990). Evaluation of the antitumor activity of gemcitabine (20, 20-difluoro-20- deoxycytidine). Cancer Res, 50, 4417-22.

12.
Juergens R, Brahmer J, Ettinger D (2007). Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer, sequence does matter. Cancer Chemother Pharmacol, 59, 621-9. crossref(new window)

13.
Kosmas C, Tsavaris N, Syrigos K, et al (2007). A phase I-II study of bi-weekly gemcitabine and irinotecan as secondline chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol, 59, 51-9.

14.
Lara PN Jr, Gumerlock PH, Mack PC, et al (2004). Gemcitabine in patients with nonsmall- cell lung cancer previously treated with platinum-based chemotherapy, A phase II California cancer consortium trial. Clin Lung Cancer, 6, 102-7. crossref(new window)

15.
Le Chevalier T. (1995). Docetaxel, meeting the challenge of nonsmall cell lung cancer management. Anticancer Drugs, 6, 13-7. crossref(new window)

16.
Lund B, Kristjansen PEG, Hansen HH (1993). Clinical and preclinical activity of 20,20-difluoro-20- difluorodeoxycytidine (gemcitabine). Cancer Treat Rev, 19, 45-55.

17.
Mattson K, Le Chevalier T, Stupp R, et al (1996). Preliminary report of Phase II study of docetaxel ($Taxotere^{(R)}$) in locally advanced or metastatic non-small cell lung cancer. Ann Oncol, 7, 429a.

18.
Robinet G, Kleisbaurer JP, Thomas P, et al (1996). Phase II study of Taxotere (docetaxel) in advanced or metastatic non-small cell lung cancer previously treated with platinum. Ann Oncol, 7, 96-7. crossref(new window)

19.
Robinet G, Kleisbaurer JP, Thomas P, et al (1997). Phase II study of docetaxel (Taxotere) in first and second-line NSCLC. Proc Am Soc Clin Oncol, 16, 480.

20.
Sculier JP, Lafitte JJ, Berghmans T, et al (2000). A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. Lung Cancer, 29, 67-73.

21.
Shepherd F, Dancey J, Ramlau R, et al (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103.

22.
Van Kooten M, Traine G, Cinat G, et al (1999). Single agent gemcitabine in pretreated patients with non-small-cell lung cancer, results of an Argentinean multicentre phase II trial. Br J Cancer, 81, 846-9. crossref(new window)

23.
van Putten JW, Baas P, Codrington H (2001). Activity of singleagent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. Lung Cancer, 33, 289-98. crossref(new window)

24.
Yokoyama A, Kurita Y, Watanabe K (1994). Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer, docetaxel cooperative study group for lung cancer. Gan To Kagaku Ryoho, 21, 2609-16.